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ABSTRACT
Hypercholesterolemia is a high risk for cardiovascular diseases, stroke, and mortality.
Multitarget directed ligands (MTDLs) with dual inhibition of Proprotein Convertase Subtilisin/
Kexin type 9 (PCSK9) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) are
the potential targets for the treatment of hyperlipidemia. Berberine (BBR), an isoquinoline
alkaloid, has been reported to reduce Low-Density Lipoprotein cholesterol (LDL-c) with no
severe side effects by increasing Low-Density Lipoprotein cholesterol Receptor (LDLR)
expression. In addition, BBR also suppressed the increased levels of PCSK9 mRNA. Therefore,
BBR might be the potent inhibitor for both enzymes. In this work, a novel series of BBR
derivatives was designed based on molecular docking to serve as MTDLs for PCSK9 and
HMGCR. The binding energy of BBR derivatives was investigated, which confirmed that all the
designed compounds showed better binding energy than the parent BBR for both enzymes.
The effect of different benzenesulfonyl ring substituents was explored to improve the binding
affinity. The obtained results indicated that there are significant differences in their interactions
and mode of binding. All 24 designed compounds were identified as potent multitarget inhibitors
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because the increase of hydrogen bond hydrophobic and electrostatic interactions were observed.
Among them, compound 12 could be selected as the best candidate for further study as potential
multitarget PCSK9 and HMGCR inhibitors for anti-hypercholesterolemia. The obtained result
suggested that the introduction of the nitro-group plays a vital role in the binding pose of the
BBR derivative. Finally, in silico study confirmed that most of the compounds pass the drug
likeliness properties.
Keywords: Berberine, HMG-CoA reductase (HMGCR), Molecular docking, Multitarget directed
ligands (MTDLs), Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9)
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Introduction
Cardiovascular diseases (CVDs) have been the leading causes of morbidity and
mortality in Western countries for decades. Elevated levels of plasma total cholesterol (TC) and
low-density plasma lipoprotein (LDL) cholesterol are major risk factors for CVDs. It is widely
acknowledged that inhibiting the cholesterol synthesis and accelerating the cholesterol
breakdown are the critical targets for controlling the TC level in the body [1]. Usually, the most
effective way to control cholesterol synthesis is by inhibiting the 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMGCR). The most widely used lipid-lowering drugs are statins.
These drugs act as competitive inhibitors of HMGCR, leading to a reduction of endogenous
cholesterol synthesis, depletion of intracellular cholesterol levels, and increase of hepatic low-
density lipoprotein receptor (LDLR) expression by up-regulating the transcription of LDLR
gene through the sterol regulatory element-binding protein (SREBP) pathway [2].
Conversely, statins have also been shown to induce the proprotein convertase
subtilisin/Kexin type 9 (PCSK9) gene identified as the third gene linked to the autosomal
dominant hypercholesterolemia through the SREBP pathway [1], as shown in Figure 1. Drug
therapy should dramatically decrease the risk of overall mortality. However, in clinical practice,
more than half of the CVDs patients do not reach their LDL-c goal; many of them undergo
cardiovascular events, even with statins as their first-line therapy [2]. Multitarget-directed ligands
(MTDLs) strategy was a recent approach for the rational design of new drug candidates.
It has been used to develop novel compounds capable of acting in diverse biological targets.
Therefore, these innovative ligands could play a vital role in advancing a broader and more
efficient therapy [3-4].
Figure 1 Regulation of the expression of LDLR and PCSK9 in the hepatic cell by statin
adapted from mediating cholesterol homeostasis through SREBP2 LDLR PCSK9
signalling [5].
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Natural products have received much attention as new therapeutic agents due to their
pharmacological features, less toxicity, and cost-effectiveness. Studies of developing natural
products as lipid-lowering agents have been reported in recent years. Berberine (BBR, Figure 1)
is a quaternary ammonium salt derived from the protoberberine class of isoquinoline alkaloids
and quite popular in the online market as a supplementary food. At present, increasing evidence
has been reported as BBR can reduce LDL-c in animals, and several clinical studies have also
tested in hypercholesterolemic patients with almost none of the side effects. Clinical studies
showed that the administration of BBR reduced LDL-c level by 20% [2], mediated by increasing
LDLR expression at the post-transcriptional level, the mechanism distinct from statins [6].
Because of its unique action and safety record, BBR is ideal for combination therapy with statins
to treat hypercholesterolemia. In addition, the combination of BBR and Simvastatin showed an
improved lipid-lowering effect with a 31.8% reduction of serum LDL-c [2]. Moreover, there are
few reports on BBRûs effects on levels of PCSK9 mRNA. It has been reported that BBR reduces
the level of PCSK9 protein secreted into the media. In addition, the combination of BBR and
mevastatin increases LDLR protein levels while suppressing the increased levels of PCSK9
mRNA caused by mevastatin alone [7]. Besides, BBR decreased PCSK9 mRNA and protein
levels in a time- and dose-dependent manner. It was not due to the increased PCSK9 mRNA
degradation but most likely to reduce transcription of PCSK9 [1]. Then, BBR might be the
potent therapeutic agent for HMGCR that reduced LDL-c level by increased expression of LDLR
like statin or/and decreased PCSK9 expression.
Nevertheless, a detailed molecular hyperlipidemia study on multifunctional PCSK9
and HMGCR inhibitors by BBR was still not deciphered. Due to the synergistic effect of BBR
and Simvastatin on reducing serum LDL-c, naphthalene moiety, which is a part of Simvastatin
and mevastatin structures (Figure 2), was designed to substitute at the C-13 of BBR. In addition,
polar substituents such as the benzenesulfonyl group were also substituted for the C-9 methyl
side chain of BBR to provide stronger binding to both targets. In this study, based on the core
structure of BBR, a novel series of naphthalene-containing BBR as multitarget PCSK9 and
HMGCR inhibitors were designed by computer-aided drug design that may represent a possible
way to solve the time-consuming as shown in Figure 2. The interaction between BBR and both
target enzymes will be allowed to characterize and explain compoundsû behavior and the detailed
structure-activity relationship (SAR) analysis via molecular docking to restrict the number of
experimental models worth testing for biochemical processes.
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Materials and Methods
1. Molecular Docking studies
1.1 Preparation of protein
The X-ray crystal structure of the human PCSK9 and HMGCR were downloaded
from the RCSB protein data bank (http://www.rcsb.org). PCSK9 (PDB code 3GCX) with a
resolution of 2.70, constructed in the presence of the EGF-A domain of the LDLR at neutral pH
[8]. In contrast, the structure of HMGCR (PDB 3CDB) was a tetramer resolved at 2.3. Chains A
and B were reserved because the binding site was composed of A and B chains [9]. Both protein
structures were firstly checked for missing atoms, residues, bonds, and contacts. Discovery studio
2020 was used to remodel both target enzymes structure by removing water molecules and
co-factors. Then, the hydrogen atoms were added to the protein using AutoDock Tools (ADT)
1.5.6 [10].
1.2 Preparation of ligands
Structures of Berberine (BBR) were downloaded from the PubChem Compound
Database (National Center for Biotechnology Information; https://pubchem.ncbi.nlm.nih.gov/).
The structures of BBR and its derivatives called ligands were energy minimized at the B3LYP/
Figure 2 Design of BBR derivatives based on the structures of BBR and statins (Mevastatin
and Simvastatin).
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6-31G (d,p) using the G09 program [11]. The stable 3D ligands were prepared in combinations
with nonpolar hydrogens, gasteiger charges, rotatable bonds based on the ADT program.
1.3 Molecular docking
Molecular docking was performed using the AutoDock 4.2 [12] package that
explores the conformational space of the ligand using the Lamarkian genetic algorithm (LGA),
which is a hybrid of a genetic algorithm (G.A.) with an adaptive local search (L.S.) method.
Ligands were docked individually to the protein with grid coordinates (grid center) and grid
boxes of specific sizes for each receptor. For PCSK9, the grid size was set at 60 x 60 x 60
(x, y, and z) points, and the grid center was designated at x, y, and z dimensions of 13.805,
-36.325, 0.195, respectively, with a resolution of 0.375. While docking study of HMGCR,
the grid size was set at 60 x 60 x 52 (x, y, and z) points, and the grid center was designated at
x, y, and z dimensions of 13.915, 6.736, 47.782, respectively. Then, the initial population
was set to 150 individuals; the maximum number of energy evaluations was 2.5 x 105, and a
root mean square deviation (RMSD) tolerance set to 2.0 angstroms, the maximum number of
generations was 27,000. Finally, the docking results were analyzed to find the best-clustered
compounds with the lowest free energy of binding. Post-docking analyses were visualized
using the Discovery Studio program, which showed the mode of binding, the intermolecular
protein-ligand interaction, and bonding distances as interaction radii of < 5 Å position the docked
ligand.
2. Analysis of drug likeliness
Bioavailability plays an essential role in the progress of bioactive compounds as
healing agents [13]. The drug-likeness properties were analyzed to select the compounds that
comply with Lipinskiûs rule of five. Accordingly, the potential orally drug is active when the
criteria of this rule were determined. Compounds are more likely permeable and active such as
molinspiration Log partition coefficient (miLogP), molecular weight, number of hydrogen bond
acceptors and donors, molecular polar surface area (TPSA), and number of rotatable bonds were
calculated by using free software (http://www.molinspiration.com/) [14].
Results and Discussion
AutoDock approach was applied to study the binding affinities of BBR
derivatives to both PCSK9 and HMGCR proteins to obtain the novel multitarget inhibitors.
The docking simulations provide insights into the possible binding modes and orientations
between ligand and protein. In the present work, the 24 designed compounds were docked into
the target proteins.
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Designing a new series of Berberine
Statins, as competitive inhibitors of HMGCR, are the most widely used lipid-lowering
drugs. These drugs improved the clearance of intracellular cholesterol levels by increased
hepatic LDLR expression. Cameron et al. studied the effect of BBR and mevastatin on the
amount of PCSK9 and LDLR mRNA. The results suggested that mevastatin has also been shown
to induce the expression of PCSK9, whereas BBR decreased PCSK9 mRNA and increased
LDLR mRNA. Besides, combining BBR and mevastatin could be helpful due to suppression
of mevastatinûs upregulation of PCSK9 mRNA [1]. To improve the therapeutic potential and
pharmacokinetic limitations of BBR, several structures were modified at the C-2, C-3, C-8,
C-9, C-10, C-12, and C-13 positions of the BBR scaffold (Figure 2) [15]. The structure-
activity relationship (SAR) analysis of BBR indicated modifications on C-9 could essentially
enhance cholesterol-lowering activity; however, there was a limited report on applying this
strategy to structure optimization at the C-9 position. Most of these studies focused on lipophilic
modifications by introducing long-chain alkyl groups [16]. Compounds 1-7 were designed
by introducing a long alkyl chain branched (n = 0-6) with the benzenesulfonyl group at the
9-position. The substituted group shared a similar structure with the previous study, compound
33 as PCSK9 modulators (Figure 3), when introduced with a sulfonamide alkyl linker,
showed very promising activity with EC50 values less than 1 nM [17]. In addition, CVI-LM001
(Figure 3), the fluorobenzenesulfonate derivative of corydaline, demonstrated increased hepatic
LDLR expression, inhibition of PCSK9 expression, and activation of AMP-activated protein
kinase (AMPK) [18].
Figure 3 Structures of small molecules as inhibitors of PCSK9.
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Also, it has been reported that the long hydrophobic alkyl chains at 13-position were
suggested to increase the bioavailability [15]. The naphthalene moiety, an HMG-CoA-like
moiety hydrophobic ring structure important in binding to the HMGR, was attached to
compound 2-8 at 13-position. The results showed that all designed compounds demonstrated
better binding energy (BE) than parent BBR, as shown in Table 1. Among them, compound
3 shows the lowest BE. The results confirmed that introducing an alkyl group at the C-9
position to BBR could decrease hypercholesterolemia, supporting the previous study [16].
The naphthalene moiety at C-13 positions of the BBR scaffold could improve the binding
affinity and might be the right candidate multitarget directed ligands (MTDLs) with dual
inhibition of PCSK9 and HMGCR.
Table 1 Binding energy (BE) of BBR and BBR derivatives to PCSK9 and HMGCR were
obtained from molecular docking studies compared to the standard drug, Mevastatin.
Compound [CH2]n BE (kcal/mol)
PCSK9 HMGCR
1 0 -7.56 -8.58
2 1 -8.00 -9.75
3 2 -7.35 -8.45
4 3 -7.52 -9.04
5 4 -7.07 -9.36
6 5 -7.40 -9.05
7 6 -6.68 -7.85
BBR - -5.50 -5.69
Mevastatin - -5.14 -7.42
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Table 2 Binding energy (BE) studied the effect of substituent group at the benzenesulfonyl ring
of BBR derivatives on PCSK9 and HMGCRs
Compound R1 R2 R3 BE (kcal/mol)
PCSK9 HMGCR
8 F H H -7.64 -8.53
9 H F H -8.14 -9.56
10 H H F -8.09 -9.95
11 NO2 H H -7.92 -11.04
12 H NO2 H -7.80 -11.56
13 H H NO2 -7.80 -11.11
14 CH3 H H -7.59 -10.20
15 H CH3 H -8.35 -10.20
16 H H CH3 -8.41 -8.85
17 OCH3 H H -7.87 -9.24
18 H OCH3 H -7.73 -9.18
19 H H OCH3 -8.18 -8.64
20 H CN H -7.47 -9.78
21 H OH H -8.03 -9.33
22 H C(CH3)3 H -8.06 -8.93
23 H Cl H -7.88 -9.46
24 H CF3 H -7.73 -8.49
BBR - - - -5.50 -5.69
Mevastatin - - - - -7.42
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Effect of substituent group at the benzenesulfonyl ring
Structure-activity relationships were investigated in order to explore the potent PCSK9
and HMGCR inhibitors. Therefore, the effect of substituent position at the benzenesulfonyl ring
was firstly focused. Compounds 8-13 contained F and NO2 represent an electron-withdrawing
group at ortho-, meta-, para-position. The obtained results indicated that there are no significant
differences in their interactions and mode of binding. An electron-donating group was CH3 and
OCH3 to give 14-19, which give similar results to an electron-withdrawing group as shown in
Table 2. The meta-position was identified as the most potent inhibitor due to strong interactions
for both enzymes. Furthermore, the different substituents on meta-position were introduced to
improve the binding affinity. The binding energy between BBR derivatives and each target
protein was shown in Table 2, and the molecular interaction was considered insight into the
binding modes.
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
The enzyme HMG-CoA reductase, an important molecular target of statins, catalyzes
the mevalonate pathwayûs reaction to convert HMG-CoA to mevalonate. Statins effectively
reduce cholesterol serum levels, attenuating cholesterol synthesis in the liver by competitive
inhibition regarding the substrate HMG-CoA. In contrast, the HMGCR binding pocket is located
between the L- and S-domains [19]. The previous study found that twenty-one residues from
neighboring monomers contribute to the binding, namely: Arg590, Ser661, Val683, Ser684,
Asn686, Asp690, Lys691, and Lys692 residues of chain A and Glu559, Gly560, Cys561,
Leu562, Ser565, Arg568, Lys735, Ala751, His752, Asn755, Ser852, Leu853, Ala856, and
Leu857 residues of chain B [20-21]. In addition, an analysis of binding energies between
compounds 9, 12, 15, 18, 20-24 and HMGCR protein showed excellent binding energies
at -8.49 to -11.56 kcal/mol (Table 2), which also better than parent BBR (-5.69 kcal/mol) and
mevastatin (-7.42 kcal/mol). Then, the docking poses of designed compounds were considered in
comparison to the standard drug. Mevastatin explored hydrogen bonds to the key residues,
including Glu559, Lys691, Lys692, and Asn755, located at the HMGCR binding site.
Remarkably, compounds 9 and 12 showed hydrogen bonding interactions similar to mevastatin.
Whereas compounds 18, 20, 21 did not involve those key residues. Interestingly, all compounds
occurred hydrophobic interactions with the amino acid comparable to the standard drug shown in
Table 3. Besides, Arg590 and His861 which found in BBR might be the crucial residues for the
electrostatic interaction. Even though the different substituent groups at the meta-benzenesulfonyl
ring significantly influenced their conformation change, those compounds are still bound to
the key residues of HMGCR. Considering the interaction, compound 12 showed the strongest
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binding affinity with HMGCR. The 2D and 3D binding posed between compound 12 and
HMGCR were shown in Figure 4(A, B). To summarize, the results indicated that introducing the
naphthalene and the benzenesulfonyl moiety increased the hydrogen bond and hydrophobic
interaction to the HMGCR binding site in comparison with BBR.
Figure 4 (A) Illustrate the 3D interaction of the best docking pose of compound 12 in the
binding sites of HMGCR (B) 2D molecular docking model of compound 12 with
HMGCR. (C) Illustrate the 3D interaction of best docking pose of compound 15 on
the surface of PCSK9 (D) 2D diagram of docking structure of compound 15 with
PCSK9. The hydrogen bonds are represented as solid green lines, hydrophobic
interactions as dashed pink and purple lines, electrostatic interactions as dash-dotted
orange lines.
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Table 3 Interactions of HMGCR amino acid residues with the different substituent groups at
meta-position of benzenesulfonyl BBR derivatives.
Compound
Amino acids involved
Hydrogen bond Hydrophobic interactions
Electrostatic
interactions
9 Glu559, Arg590, Ser684, Lys691, Leu562, Ala564, Ser565, His752, Arg590
His752, Asn755, His861 Leu853, Ala856
12 Glu559, Arg590, Ser684, Lys691, Leu562, Met657, His752, Leu853, Arg590, His861
Lys692, Lys735, Asn755 Ala856, Leu857, His861
15 Arg590, Lys691, His752, Cys561, Leu562, Ala564, His752, Arg590
Asn755, His861 Leu853, Ala856, Leu857
18 Thr558, Gly560, His861 Cys561, Leu562, Lys662, Leu853, Glu559, Lys691
Ala856, Leu857, His861
20 Ala525, Thr558, Gly560, Asn658, Cys561, Leu562, Leu853, Ala856, Glu559, His861
Gly808 Leu857, His861
21 Ala525, Thr558, Gly560, Asn658, Cys561, Leu853, Ala856, Leu857, Asp767, His861
Gly808, Ala856 His861
22 Lys691, Asn755 Leu562, Met657, Lys662, Leu853, Arg590, Glu559,
Leu857, His861 His861
23 Ala525, Glu559, Gly560, Asn658, Cys561, Ala654, Met655, Met657, His861
Ala856 Leu853, Ala856, Leu857, His861
24 Lys691, His752, His861 Cys561, Leu562, Ala564, Met657, Arg590, Asp690,
His752, Leu853, Ala856  His861
BBR Ser684, Lys735, Ala751 Met657, Leu853, Ala856, Leu857 Arg590, His861
Mevastatin Glu559, Lys691, Lys692, Leu562, Met657, Val683, His752, -
 Asn755 Leu853, Leu857, His861
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9)
Multiple clinical studies have shown that injectable antibody therapeutics that impede
the PCSK9-LDLR protein-protein interaction (PPI) significantly decrease circulating LDL levels.
Subsequently, two antibody drugs that disrupt PCSK9-LDLR were FDA approved; they appear
to be tolerated well, with no severe side effects and are efficacious. Small molecule drugs have
been the preferred modality for disruption of PCSK9-LDLR; however, based on the mode of
administration, cost, shelf life, and immunogenic response issues [8]. PCSK9 binds to LDLRs on
the cell surface, leading to their degradation. The binding site of PCSK9 localizes the epidermal
growth factor A (EGF-A) domain of the LDLR. The critical interactions of PCSK9 with EGF-A
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are between residues 377-379 of PCSK9. Also, Arg194, Asp238, Ile369 of PCSK9 are
essential for the binding [18]. BBR was reported to down-regulate PCSK9 [1]. In the molecular
study, BBR interacted with three key residues; hydrophobic interaction formed with Ile369,
Phe379, and strong hydrogen bond with Arg194. While compounds 9, 12, 15, 18 and 20-24
were investigated, focusing on the different substituent groups on meta-position at the
benzenesulfonyl ring. The results showed significant differences in their interactions and binding
mode. All compounds interacted well with PCSK9 showing binding energies of -7.47 to -8.35
kcal/mol (Table 2), which better than BBR (-5.50 kcal/mol). Most designed compounds
correlated with PCSK9 protein by forming two hydrogen bonds with Arg194, Phe379.
In addition, all compounds involved with two amino acids in hydrophobic formation interactions;
Ile369, Phe379, except compound 22. For an electrostatic interaction, compounds 12, 18, 21,
and 24 were formed with Arg194. Interestingly, the result indicated that hydrophobic interaction
was the main contribution for BBR derivatives to bind with PCSK9 shown in Table 4. From
this set of compounds, the meta-NO2 substituent at the benzenesulfonyl moiety (15) showed the
lowest BE. The docking posed of compound 15 located on the surface of PCSK9 which shown
in Figure 4(C). The 2D interactions were clearly explained in Figures 4(D). Finally, the novel
BBR derivatives established similar binding modes to the PCSK9 binding site as compared
to EGF-A.
Table 4 Interactions of PCSK9 amino acid residues with the different substituent groups at meta-
position of benzenesulfonyl BBR derivatives.
Compound
Amino acids involved
Hydrogen bond Hydrophobic interactions Electrostatic
interactions
9 Arg194, Phe379 Pro155, Ala239, Ile369, Phe379, Val380 -
12 Arg194, Phe379, Ser381 Pro155, Ala239, Ile369, Phe379, Val380 Arg194
15 Arg194, Phe379 Pro155, Ala239, Ile369, Phe379, Val380 -
18 Arg194, Thr377, Phe379 Pro155, Ala239, Ile369, Phe379, Val380 Arg194
20 Phe379, Ser381 Ile369, Phe379 -
21 Arg194, Ser372, Phe379 Pro155, Ala239, Ile369, Phe379, Val380 Arg194
22 Arg194, Thr377, Phe379 Ala239, Cys375, Cys378, Phe379,  Val380 -
23 Arg194, Phe379, Ser381 Pro155, Ala239,  Ile369, Phe379, Val380 -
24 Arg194, Thr377, Phe379 Pro155, Ala239, Ile369, Phe379, Val380 Arg194
BBR Arg194 Ile369, Phe379 -
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Drug likeness
The observation of the most biologically active drugs was evaluated by Lipinski’s
rule of five. This simple rule is based on a molecular weight (MW) of approximately 500,
log P values not exceeding 5, hydrogen donor bond (HBD) not more than 5, and hydrogen
bond acceptor bond (HBA) not greater than 10. The bioavailability of drugs links to the polar
topological surface (TPSA) and the number of rotatable bonds (nRB) [22]. The molecular
properties of ten designed compounds were calculated using molinspiration software compared
to standard drugsû values: mevastatin and the natural product (BBR). Considering these
recommendations, the results presented in Table 5 indicate that all the compounds analyzed have
MW > 500. So, they have poor drug distribution that depends on drug size and lipophilicity,
confirmed by miLogP. The value of miLogP must be estimated 0.4 to 5; the obtained results
showed that most of the compounds agree with miLogP, except 22 miLogP value > 5. Highly
lipophilic value was indicated that drug only be absorbed after dissolving in the digestive tract.
In addition, TPSA and nRB are a perfect descriptor characterizing drug absorption, including
intestinal absorption, bioavailability, and penetration of the blood-brain barrier. The designed
compounds showed TPSA < 140 Å2 and nRB < 10. Then, they should exhibit good intestinal
absorption. In addition, low TPSA and total hydrogen counts (HBD and HBA) are significant
predictors of good oral bioavailability. All compounds passed the evaluation (HBD and HBA
counts) and qualified to be used as drugs. Furthermore, the designed BBR derivatives fulfill the
Lipinskiûs rule, which implies potent oral bioavailability multitarget inhibitors, except 22.
Dual binding inhibitor of novel Berberine derivatives
A recent approach for the rational design of the MTDLs approach has gained
increasing attention, which has developed various hybrid compounds acting simultaneously on
diverse biological targets such as Alzheimerûs disease [23]. Hypercholesterolemia is the risk
factor of mortality; however, more than 50% of patients do not reach their goal for prevention
and treatment. In the present work, the novel series of BBR derivatives were designed based on
in silico study as the multitarget inhibitor for anti-hypercholesterolemia. To summarize,
the obtained docking studies of all compounds to both target enzymes clearly explained the
molecular rationality design. Most of them showed satisfying results in the mode of binding,
binding affinity, and drug-likeness properties, except compound 22; MW > 500, miLogP > 5.
In considering, 12 is the meta-NO2 substituent at the benzenesulfonyl moiety, chosen as the
excellent candidate for further development to be the lead compound. It showed the binding
affinity to PCSK9 and HMGCR at -7.38 and -11.56 kcal/mol, respectively. More importantly,
12 showed a similar mode of binding to the previous works concerning PCSK9 [18] and
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HMGCR [20], making it a highly potent inhibitor than other compounds. Through analysis, the
NO2-substituent group enhanced the binding affinity of BBR derivatives to both target enzymes,
as shown in Figure 5. Considering PCSK9, BBR scaffold, and the naphthalene moiety occurred
much hydrophobic interaction through the residues Pro155, Ala239, Ile369, and Phe379 via
Pi-alkyl, alkyl. In addition, the core structure of BBR formed electrostatic interaction with Arg194
residue. The benzenesulfonyl moiety generated Pi-sulfur to key residue Cys378, hydrophobic
interaction with Val380, and hydrogen bond via SER381. Interestingly, the key residue Phe379
generated a conventional hydrogen bond and Pi-lone pair with the nitro- group, as shown in
Figure 5(A). For HMGCR binding, ring A of BBR structure occurred electrostatic interaction
with His861. Five hydrophobic interactions formed to ring B (Met657), ring D (Leu853), and
methyl at C-10 position (Leu562 and His752). The naphthalene moiety in the BBR scaffold
was established hydrophobic with Ala856, Leu857, and electrostatic interactions through
His861. The benzenesulfonyl moiety showed hydrogen bonds with Lys691, Asn755, generated
electrostatic interactions of the benzyl group through Arg590 and formed hydrophobic
Table 5  Physicochemical properties of meta-benzenesulfonyl ring-containing BBR derivatives.
Compound MW miLogP HBA HBD TPSA nRB
2 616.72 3.73 7 0 74.96 7
9 634.71 3.87 7 0 74.96 7
12 661.71 3.66 10 0 120.79 8
15 630.74 4.15 7 0 74.96 7
18 646.74 3.76 8 0 84.20 8
20 641.73 3.46 8 0 98.75 7
21 632.71 3.22 8 1 95.19 7
22 672.82 5.41 7 0 74.96 8
23 651.16 4.38 7 0 74.96 7
24 684.71 4.60 7 0 74.96 8
BBR 336.37 0.20 5 0 40.82 2
Mevastatin 404.55 4.35 5 1 72.84 7
MW: Molecular Weight; miLogP: molinspiration Log partition coefficient; HBA: Hydrogen bond
acceptor; HBD: Hydrogen bond donor; TPSA: topological polar surface area; nRB: Number
of rotatable bonds.
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interaction with Leu853. Surprisingly, the nitro-group formed five conventional hydrogen bonds
to Arg590, Ser684, Lys692, and Lys735, which play an essential role in HMGCR binding, as
shown in Figure 5(B).
Conclusion and Discussion
A novel series of berberine derivatives as multifunctional inhibitors has been
designed and evaluated the binding affinities for PCSK9 and HMGCR. The obtained results
showed that most of the designed compounds exhibited strong binding interactions to both target
proteins than the parent BBR and the standard drugs (Mevastatin). Hence, the introducing
aromaticity at the C-13 position and benzenesulfonyl moiety at the C-9 position increases the
binding affinity of BBR derivatives. The different benzenesulfonyl substituents improved
the binding mode and orientation, enhancing the possibility of binding with key residues.
Additionally, in silico study confirmed that most of the compounds fulfilled drug-likeness
properties. Finally, further experimental approaches can be applied to prove that the novel
berberine derivatives can be further developed as potential multitarget PCSK9 and HMGCR
inhibitors for hypercholesterolemia treatment.
Figure 5 2D interactions between 12 and target proteins (A) PCSK9 (B) HMGCR. The hydrogen
bonds are represented as solid green lines, hydrophobic interactions as dashed pink
and purple lines, electrostatic interactions as dash-dotted orange lines.
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